This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
Kidney Cancer
RadiCal
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
FORT
NRG-GU 0101
Masofaniten (Oral EPI-7386)
RTIRE
SHORTER
SPLASH
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Suprapubic Catheter
Diane K. Newman, DNP FAAN BCB-PMD
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Pelvic Health & Reconstruction
Endourology
Testicular Cancer
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASTRO 2023
SNMMI 2023
ProsTIC/PCF Global Webinar 2023
ASCO 2023
AUA 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO 2023
ASCO 2023
Prostate Cancer
Testicular and Penile Cancer
Press Releases
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Carcinoma
ASCO 2023 Kidney Cancer
Viewing 1-20 of 32 articles
ASCO 2023: When Is Stereotactic Ablative Body Radiotherapy an Option?
ASCO 2023: The Role of Cytoreductive Nephrectomy and Surgical Metastatectomy
ASCO 2023: When to Play the Systemic Therapy Card
ASCO 2023: Doublet and Triplet Therapy for Metastatic RCC: Factors That Influence Decision-Making
ASCO 2023: Doublet and Triplet Therapy for Metastatic RCC: The Case for Triplet Therapy
ASCO 2023: Doublet and Triplet Therapy for Metastatic RCC: The Case for Doublet Therapy
ASCO 2023: Discussant: Combination Therapies Come of Age in Kidney Cancer
ASCO 2023: Final Prespecified Overall Survival Analysis of CLEAR: 4-Year Follow-up of Lenvatinib + Pembrolizumab vs Sunitinib in Patients with Advanced RCC
ASCO 2023: Pembrolizumab + Axitinib Versus Sunitinib as First-Line Therapy for Advanced Clear Cell RCC: 5-Year Analysis of KEYNOTE-426
ASCO 2023: Efficacy and Safety of Atezolizumab + Cabozantinib vs Cabozantinib Alone After Progression with Prior Immune Checkpoint Inhibitor Treatment in Metastatic RCC: Primary PFS Analysis from the Phase 3, Randomized, Open-Label CONTACT-03 Study
ASCO 2023: NRG-GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Patients with Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
ASCO 2023: LITESPARK-024: Randomized Phase 1/2 Study of Belzutifan with or Without Palbociclib for Treatment of Advanced Renal Cell Carcinoma (RCC)
ASCO 2023: Poster Discussant: Adding Clarity to Non-Clear Cell Carcinoma
ASCO 2023: Pathologic Concordance Rate and Outcomes by Histologic Subtype in Advanced Papillary Renal Cell Carcinoma: An Analysis from the SWOG S1500 (PAPMET) Trial
ASCO 2023: Phase 1b/2 Study of Combination 177Lu Girentuximab + Cabozantinib and Nivolumab in Treatment Naïve Patients with Advanced Clear Cell RCC
ASCO 2023: Efficacy of First-Line Immunotherapy - Based Regimens in Patients with Sarcomatoid And/or Rhabdoid Metastatic Non-Clear Cell Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consort
ASCO 2023: First-Line Lenvatinib + Pembrolizumab Treatment Across Non-Clear Cell Renal Cell Carcinomas: Results of the Phase 2 KEYNOTE-B61 Study
ASCO 2023: Phase II Study of Cabozantinib with Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma with Variant Histologies
ASCO 2023: CABOSUN II: Results from a Phase 2, Open-Label, Multi-Center Randomized Study of Cabozantinib vs. Sunitinib for Non-Clear Cell RCC
ASCO 2023: Real-World Outcomes Among Patients with Advanced/metastatic RCC Treated with Cabozantinib or Other TKIs After Checkpoint Inhibitor Therapy
1
2
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free